Clinical Trial Update: Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 trial update on deferasirox for iron overload after donor stem cell transplant; study terminated with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Iron Overload

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Breast Cancer, Iron Overload | Phase 2 | Status: TERMINATED | Results posted: 2010-03-30